ACP
KZR

Acuta Capital Partners’s Kezar Life Sciences KZR Stock Holding History

Acuta Capital Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$1.73M – 41
2018
Q2 		$1.73M Buy
+10,000
New +$1.74M 0.31% 44

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Acuta Capital Partners's KZR Position: Q3 2018 in Review

Acuta Capital Partners sold out of Kezar Life Sciences (KZR) in Q3 2018, closing a stake of 10,000 shares — an estimated $1.73M sold.

Acuta Capital Partners first reported a position in KZR in Q2 2018 and held it in 1 quarter. The position peaked at $1.73M in Q2 2018. 37 funds tracked by Wall St. Rank hold KZR as of Q3 2018.

  • Acuta Capital Partners reported no remaining Kezar Life Sciences position as of Q3 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 10,000 Kezar Life Sciences shares in Q3 2018, an estimated $1.73M.
  • Acuta Capital Partners first reported a position in Kezar Life Sciences in Q2 2018 and held it in 1 quarter.
  • Acuta Capital Partners's Kezar Life Sciences position peaked at $1.73M in Q2 2018.
  • 37 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2018.

Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.